Board of Directors

Murray Ross is Vice President, Kaiser Foundation Health Plan, Inc. and leads the Kaiser Permanente Institute for Health Policy in Oakland, California. Kaiser Permanente is the largest private integrated health care delivery system in the U.S., serving over 10 million people in eight states and Washington, D.C. The Institute seeks to shape public policy and private practice by sharing evidence and experience from Kaiser Permanente’s operations through publications, expert roundtables, and conferences. Dr. Ross speaks frequently to domestic and international audiences on a wide range of health care topics and serves on a number of academic and non-profit boards. His current work focuses on how American health care can make better use of new medical technologies and how public policy can support better alignment of clinical and financial decision-making to improve health and the quality and affordability of health care. He also has a long-standing interest in improving communications in health care, both between patients and providers and also between knowledge producers and policy influencers.

Before joining Kaiser Permanente in 2002, Dr. Ross was a policy advisor to the U.S. Congress, first at the Congressional Budget Office and later as the executive director of the Medicare Payment Advisory Commission.

An economist by training, Dr. Ross earned his doctorate at the University of Maryland, College Park, and completed his undergraduate work at Arizona State University. He enjoys distance running, writing, photography, and traveling (often together).

With a breadth of health care experience spanning several decades, Dr. Wendy Everett was chosen to oversee the formation of the Network for Excellence in Health Innovation (NEHI) in 2002 as its first president. Dr. Everett now serves as NEHI's Executive Chair of the Corporation where she oversees the operations and strategic direction of the organization.

Along with NEHI’s founders, Dr. Everett’s vision was to create an independent, research-based organization that convened diverse members of the health care industry to achieve the common goal of addressing the most urgent health care issues. Under her leadership, this vision resulted in ground-breaking research on medical innovation, patient safety, health care spending and health care information technology, and has influenced significant national policy changes.

Previously, Dr. Everett held executive positions at the University of California, San Francisco Medical Center (UCSF) and Brigham and Women’s Hospital in Boston. She has directed national demonstration programs for the Robert Wood Johnson Foundation and the Kaiser Family Foundations.

In addition, Dr. Everett served as Vice Chair of the Massachusetts Health Policy Commission, an independent state agency that monitors the reform of the health care delivery and payment systems in Massachusetts. She also serves on the boards of many philanthropic foundations and non-profit organizations.

Dr. Everett earned two bachelor of science degrees and holds master’s and doctoral degrees in health policy and management from Harvard University.

Jonathan J. Fleming is Treasurer of NEHI's Board of Director and Currently serves as the Chief Business Officer of Q-State Bioscience. Since 1999, Mr. Fleming has been the Managing Partner of Oxford Bioscience Partners, an international venture capital firm specializing in life science investments, based in Boston, MA. Mr. Fleming has been in the investment business for more than 31 years, starting and financing growth companies in the United States, Europe, Israel and Asia. Prior to joining Oxford Bioscience Partners in 1996, he was a Founding General Partner of MVP Ventures in Boston, MA. He began his investment career with TVM Techno Venture Management in Munich, Germany. Mr. Fleming also co-founded Medica Venture Partners, a venture capital investment firm specializing in early stage health care and biotechnology companies in Israel, and the Korea Seoul Life Science Fund, based in Seoul, Korea. Mr. Fleming is a director of Xencor (NASDAQ: XNCR) and several private early stage life science companies. He is also a director of Leerink Partners, a Boston based investment bank specializing in health care companies. In addition, Mr. Fleming has been a Senior Lecturer at the MIT Sloan School of Management since 2003, where he co-teaches a class on business strategy for life science managers. Mr. Fleming holds a Master's degree in Public Administration from Princeton University’s Woodrow Wilson School of Public and International Affairs, and a Bachelor's degree in Political Science from the University of California, Berkeley.

Barbara A. DeBuono, M.D., M.P.H. is Vice President for Clinical Strategy and Value Based Care at 3M Health Information Systems. She has led and managed large healthcare organizations and budgets in government and the private sector during her career as a public health physician. Dr. DeBuono served as Commissioner of Health for the State of New York in the first term of Gov. George Pataki, having previously served as Director of Health in Rhode Island in the cabinet of Gov. Bruce Sundlun. In both roles Dr. DeBuono led efforts to develop Medicaid Managed Care and SCHIP programs and crafted HIV, immunization, and breast and cervical cancer prevention policies. Following her role as Commissioner, she joined the New York-Presbyterian Health System in New York City serving as Executive Vice President of its network. Dr. DeBuono also served as Executive Director, Public Health and Government at Pfizer Inc., senior consultant to the World Health Organization (WHO), and Senior Partner and Global Director of Health and Social Marketing at global public relations leader Porter Novelli. She serves as a member of the Dean’s Council at The George Washington University School of Public Health and Health Services, where she is a Professorial Lecturer in the Department of Health Policy.

Chris Coburn is Vice President, Innovation, Partners HealthCare. Based in Boston, Partners is largest academic research enterprise in the United States with greater than $1.5 billion in annual research. The Partners HealthCare system consists of Massachusetts General Hospital and Brigham and Women’s Hospital – ranked #1 and #6 in the nation, respectively, by US News & World Report – as well as McLean Hospital and others. Partners faculty are appointed at Harvard Medical School.

Mr. Coburn leads a team of more than 80 tasked with the commercial application of the discoveries and unique capabilities of Partners’ 60,000 employees. His unit’s responsibilities include business development, company creation, licensing, investment, cooperative agreements, and management of all technological breakthroughs of Partners’ staff. 2015 commercialization revenue exceeded $110 million.
Prior to joining Partners, Mr. Coburn founded Cleveland Clinic Innovations and served for 13 years as its Executive Director. During his tenure Cleveland Clinic spun off 57 companies that raised more than $700 million in equity financing. Cleveland Clinic had no technology based spin-offs before Coburn’s arrival. He also implemented a national Innovation Alliance in which Cleveland Clinic managed technology commercialization for healthcare systems throughout the United States.
Mr.Coburn has served on numerous corporate and community boards including Explorys (acquired by IBM), Autonomic Technologies, and the U.S. Enrichment Corporation (NYSE:USU). He was a member of the National Academy of Sciences Committee on Assessing the Value of Research in Meeting National Goals. He is a former Vice President and General Manager of Battelle Memorial Institute. He has consulted, testified and spoken on innovation and commercialization throughout North America and in more than 30 countries. He and his wife, Nancy, have three grown children.

Dr.Fallon has recently retired from being the Chief Physician Executive and Senior Vice President at Blue Cross Blue Shield of Massachusetts for over eight years. He is responsible for ensuring the highest standards of medical care for its members. He is also accountable for helping expand health care strategies involving quality, effectiveness, efficiency and their relationships to new payment methodologies. He oversees the company’s medical policies, acts as the main liaison with the plan’s provider network, reviews upcoming legislation for medical impact, manages the company’s medical directors, acts as primary spokesperson for medical inquires and is the main medical contact with the National Blue Cross Blue Shield Association and its 39 plans across the country, covering almost 100 million members.

Prior to coming to BCBSMA, he was CEO for the entire clinical enterprise at the State University of New York’s Downstate Medical Center, including University Hospital of Brooklyn and the clinical faculty practice plan. He still maintains his academic appointment as Clinical Professor in the Graduate Program of Public Health. His professional experiences also include the Partners Healthcare System, where he was Chairman of the physician network. Dr. Fallon was also the founder and CEO of North Shore Health System, a large physician-hospital organization in Massachusetts. He is Chair of the National Council of Physician Executives at the Blue Cross Blue Shield Association.

Dr. Fallon serves as the Chair of NEHI's Board of Directors, and formerly served on the boards of NCQA Medical Standards (former Chair), New England Comparative Effectiveness Public Advisory Council (CEPAC) and Temple University School of Medicine Board of Advisors. Dr. Fallon practiced Internal Medicine for over 20 years; did his residency at Boston City Hospital; is Board Certified in Internal Medicine; and is a Fellow of the American College of Physicians.

Bob Filippone is Vice President, U.S. Policy and Government Relations at Merck. Bob and his team represent Merck in Washington, DC, and are responsible for U.S. policy development and legislative advocacy on Merck’s key federal issues. They also oversee the administration of the Merck PAC and the company’s grassroots program.

Bob joined Merck from PhRMA, the Pharmaceutical Research and Manufacturers of America, where he served as Senior Vice President, Federal Affairs. Bob led PhRMA’s Federal Affairs team with responsibility for advancing PhRMA’s interests with members of congress and the administration.

Prior to his time at PhRMA, Bob served as the Deputy Chief of Staff in the office of U.S. Senator Bob Graham (D-FL). He was Senator Graham’s principal advisor on foreign policy, homeland security, intelligence, defense and international trade issues.

During his tenure with Senator Graham, Bob also held the position of Deputy Staff Director for the Senate Select Committee on Intelligence. The Committee is responsible for conducting oversight of the U.S. intelligence community and for authorizing intelligence activities of the U.S. Government.

Prior to joining Senator Graham’s staff, Bob worked as a national security specialist in the Office of the Secretary of Defense in Washington. He has also worked as a fellow in the Bureau of Intelligence and Research at the Department of State, as a missile systems engineer at the Raytheon Company, and has taught international relations at the Fletcher School of Law and Diplomacy at Tufts University.

Bob holds Ph.D. and Master’s degrees in international relations from the Fletcher School of Law and Diplomacy, and Bachelor’s and Master’s degrees in engineering from Worcester Polytechnic Institute. He is married to Desiree Geneva Filippone and they have two sons and a daughter.

Paul joined Tufts Health Plan in 2010 as chief medical officer. He is responsible for overseeing the 300-member health care services staff and for developing strategies for improving medical outcomes and reducing costs. Additionally, Paul helps Tufts Health Plan to develop new opportunities to partner with area hospitals and physicians. He also serves as the clinical spokesperson to members, legislators, regulators and the media.

Most recently, Paul was chief of the division of internal medicine at St. Elizabeth's Medical Center in
Boston and assistant clinical professor of medicine at Tufts University School of Medicine. While at St. Elizabeth's, Paul served as vice president and medical director of the Caritas Physician Network's community practice division and president of St. Elizabeth's Health Professionals IPA.

Paul served as chair of the Medical Directors Committee for the Alliance of Community Health Plans
working to help shape the committee's strategic priorities to promote high quality, affordable care and superior consumer experience for ACHP members. He currently serves as the Vice-Chairman for the BOD at Martin’s Point Health in Maine. A member of the American Medical Association and the Massachusetts Medical Society, Paul currently maintains a limited private internal medicine practice.

Paul is a graduate of Tufts University School of Medicine and completed his medical training at St.
Elizabeth's Medical Center in Boston. He received his B.A. with honors in political science from Duke University.

Rubén José King-Shaw, Jr., is the Chief Strategy Officer of Steward Health Care System and President of Steward Health Care Network. Mr. King-Shaw previously held the position of Chairman and Chief Executive Officer of Mansa Equity Partners, Inc, and was a member of Steward Health Care System’s board of directors. Throughout his career, he has spent considerable time in public service leading both state and federal government health programs. At the state level, under Florida Governor Jeb Bush, Mr. King-Shaw was the Secretary of the Florida Agency for Health Care Administration. The Agency was responsible for Florida’s State Medicaid Program, Health Quality Assurance, Survey and Certification of healthcare facilities, Managed Care and the Child Health Insurance Program (CHIP).

Mr. King-Shaw also served as Deputy Administrator and Chief Operating Officer of the Centers for Medicare and Medicaid Services (CMS) from 2001 to 2003 during the administration of President George W. Bush. He was also senior advisor to the Secretary of the U.S. Treasury, where he led the Administration's Health Coverage Tax Credit policies to finance coverage for the uninsured. In 2011, Mr. King-Shaw was appointed to the Obama Administration's Program Advisory and Oversight Committee to monitor and provide guidance to Medicare's value-based purchasing program for Durable Medical Equipment. Currently, he is an advisor to the Trump Administration in the areas of fraud, waste and abuse, and alternative payment models.

Liz Lewis, JD is Head of Patient Value, Policy and Advocacy for the Global Oncology Business Unit at Takeda where she is responsible for accelerating Takeda’s efforts in securing rapid and broad patient access and continuing to strengthen Takeda’s patient advocacy, access and policy approach and initiatives. Prior to this role, Ms. Lewis was the Chief Counsel for the Specialty Business Units and R&D and Head of Patient Advocacy at Takeda Oncology, where she was responsible for setting the company’s global legal strategies and priorities and managing the day-to-day legal activities for the Specialty Business Units and R&D. Ms. Lewis also headed the patient advocacy team, partnering closely with oncology patient advocates and patient advocacy groups throughout the world to support access to cancer therapies. She provides strategic insight into patient programs with a focus on access and assistance programs.

During her more than 15 years with the company, Ms. Lewis was instrumental in building legacy Millennium Pharmaceutical’s legal and compliance functions that serve as the foundation for Takeda’s Global Oncology Business Unit. Her pharmaceutical legal experience is broad, with expertise in research and product development, product commercialization, launch, market access/pricing and compliance. She played an integral role in the company’s successful launch, commercialization and market expansion of multiple oncology products, including VELCADE® (bortezomib), NINLARO® (ixazomib) and, most recently, ALUNBRIG® (brigatinib).

Prior to joining Millennium/Takeda, she served as partner at the Washington DC-based law firm, Epstein, Becker and Green, where she represented health care and life science companies, working her way up to co-chair the firm’s pharmaceutical practice group. She has spoken, conducted seminars and published numerous articles on intricate health-related subjects such as commercial practices and strategies in the pharmaceutical industry, health care corporate compliance, health care fraud and federal program reimbursement. An active participant in industry trade organizations, Ms. Lewis is on the board of directors for Massachusetts Biotechnology Council (MassBio) and a member of the Health Section Governing board for Biotechnology Innovation Organization (BIO).

Ms. Lewis obtained her law degree from Washington College of Law at American University serving as an editor for the Administrative Law Journal. She earned her BA in Political Science from Hamilton College, where she graduated with honors. The Boston Business Journal named Ms. Lewis as one of the top 20 “2014 Women to Watch” in the life sciences industry.

Mark E. Lutes is the Chair of the firm’s Board of Directors and a Member of the the firm’s Health Care and Life Sciences practice. Based in Washington, DC, he has practiced with the firm for more than three decades. Prior to that, he was a legislative adviser to the Federal Trade Commission. He also offers strategic counsel in health policy and on reimbursement strategy through the firm's affiliates EBG Advisors, Inc., and National Health Advisors, LLC.

Mr. Lutes is a leader in the firm's representation of private equity and financial services firms with health care companies in their portfolios. He routinely deploys multidisciplinary teams of attorneys, reimbursement specialists, engineers, and scientists to assess the reimbursement, FDA and other domestic and international regulatory approvals, fraud and abuse compliance, CMS and legislative landscapes and other issues impacting proposed client investments in health care companies.

Mr. Lutes combines experience with the corporate aspects of transactions with his deep experience in health care compliance issues to provide clients with practical advice in the negotiation of warranty and indemnification issues and in assessing risk factors in health and life science deals. He has advised on the largest transactions in the health care market including services, pharmaceutical and device companies.

Mr. Lutes is also an experienced antitrust counselor to health care companies contemplating mergers or acquisitions and has facilitated the antitrust clearance of numerous significant hospital mergers. He has managed the defense of high profile healthcare antitrust actions by the FTC.

Mr. Lutes has a deep understanding of managed care markets and regulation. He is consulted by a variety of providers and payors in structuring innovative payment arrangements. Additionally, he counsels on hospital and physician ventures and compliance issues and in the area of information privacy and security. Mr. Lutes has developed privacy and security audit tools which support client compliance needs.

David Meeker joined KSQ from Sanofi, where he was a member of the executive committee and Head of Sanofi-Genzyme. He previously served as President and CEO of Genzyme (a Sanofi company) following the merger of Genzyme and Sanofi. Post-merger at Sanofi-Genzyme, David assumed responsibility of the rare disease unit and the launch of the company’s new multiple sclerosis franchise, and he was given responsibility for the full specialty-care portfolio of Sanofi, adding the oncology and immunology portfolios. In that capacity, he oversaw the initial launch of products for atopic dermatitis and rheumatoid arthritis. David joined Genzyme in 1994 to work on the cystic fibrosis gene therapy program and ultimately served in a variety of R&D leadership roles before moving to operational roles with increasing responsibility beginning in the year 2000. He was named COO of Genzyme in 2009, with broad responsibility for the global commercial portfolio. Prior to joining Genzyme, David was a practicing physician at Cleveland Clinic, with a specialty in pulmonary and critical care. He did his internal medicine training at Harvard’s Beth Israel Deaconess Medical Center and his pulmonary/critical care training at Boston University. He currently serves as chairman of the board of Rhythm Pharmaceuticals and Trevi Therapeutics, and he is a member of the board of Myokardia. He also serves on the boards of the Biomedical Science Careers Program and the Network for Excellence in Health Innovation.

David received his MD from the University of Vermont Medical School. He completed the Advanced Management Program at Harvard Business School.

Bruce is the Chief Physician Executive for Blue Cross Blue Cross Blue Shield of Massachusetts, the largest private health plan in Massachusetts and one of the largest independent, not-for-profit Blue Cross Blue Shield plans in the country. The company has more than $7 billion in revenue, serves nearly 3 million members, and is rated among the nation’s best health plans for overall member satisfaction and quality.

Bruce leads the Health and Medical Management Division, which is responsible for care and utilization management activities for medical and behavioral health. He is the senior clinical leader who guides health care strategies designed to improve the quality and affordability of health care.

He has over 25 years of health care management and clinical experience in medical group practice, hospital and managed care settings. He has held leadership positions at Capital District Physicians’ Health Plan and Kaiser Permanente and served as President of the former North Adams Regional Hospital in Massachusetts.

He currently serves on the boards of the Blue Cross Blue Shield Foundation, the Network for Excellence in Health Innovation and the Greater Boston Food Bank. Bruce earned his undergraduate degree at Rensselaer Polytechnic Institute and his medical degree at Albany Medical College. He is a board-certified family physician who completed his residency training at Duke University. He also received an MBA in health sector management from Duke University's Fuqua School of Business.

Dr. Samuel Nussbaum is executive vice president, clinical health policy and chief medical officer for WellPoint, Inc. He oversees corporate medical policy, clinical pharmacy programs, programs in clinical excellence, and health information technology. His principal responsibilities include: serving as chief spokesperson and policy advocate on medical issues, guiding the corporate vision regarding quality of care and its measurements, leading efforts to assess clinical quality performance and safety and developing a strategy to foster further collaboration with physicians and hospitals and national organizations (such as CDC and FDA) to strengthen and improve patient care. Dr. Nussbaum also has responsibility for HealthCore, WellPoint’s clinical outcomes research subsidiary.

Dr. Nussbaum has served as president of the Disease Management Association of America, Chairman of the National Committee for Quality Health Care, as Chair of America's Health Insurance Plan's (AHIP) Chief Medical Officer Leadership Council and as a member of the AHIP Board, and currently serves on the National Quality Forum (NQF) Board and on the Secretary of Health and Human Services Advisory Committee on Genetics, Health, and Society. He received the 2004 Physician Executive Award of Excellence from the American College of Physician Executives and Modern Physician magazine. Dr. Nussbaum is professor of clinical medicine at Washington University School of Medicine and serves as adjunct professor at the Olin School of Business, Washington University.

Dr. Nussbaum served as executive vice president, Medical Affairs and System Integration, of the BJC Health Care, where he led integrated clinical services across the health system and served as President of its medical group.

Dr. Nussbaum earned his medical degree from Mount Sinai School of Medicine. He trained in internal medicine at Stanford University Medical Center and Massachusetts General Hospital and in endocrinology and metabolism at Harvard and Massachusetts General Hospital, where he directed the Endocrine Clinical Group. Dr. Nussbaum served as a professor at Harvard Medical School where his clinical and basic research has led to new therapies to treat skeletal disorders and new technologies to measure hormones in blood.

Mr. von Rickenbach is the Managing Director of stet vision LLC. Prior to stet vision, Mr. von Rickenbach was co-Founder, President & CEO of biotech company Helio Vision, Inc., which was successfully merged with Aldeyra Therapeutics (NASDAQ: ALDX) in early 2019. Previously, Mr. von Rickenbach was co-Founder, Chairman & CEO of PAREXEL International Corporation. He took the company from its pioneering beginnings, as one of the first clinical research organizations (CROs) in the early 1980s, to its place as one of the top three global biopharmaceutical services providers.  He led PAREXEL through multiple rounds of venture capital, multiple secondary offerings, and over 40 mergers and acquisitions during his 36-year history at the helm of the Company. In a “going private” transaction in 2017, PAREXEL was acquired for $5 billion by a private equity firm.

Foreseeing the globalization of clinical research, Mr. von Rickenbach worked to expand PAREXEL’s presence to 51 countries. This extensive geographical presence and the Company’s 20,000 employees allow PAREXEL to conduct clinical trials across every continent in more than 100 countries. To make clinical development more effective, he conceived a multidisciplinary and systems-oriented approach to clinical development, bringing efficiencies, scalability, and standardization to the process.  As biopharmaceutical R&D adopted information technology, Mr. von Rickenbach instituted a leading advanced technology offering with PAREXEL Informatics, a frontrunner in providing eClinical solutions. 
 
Mr. von Rickenbach was a founding member of the Board of Directors of the Association of Clinical Research Organizations (ACRO) and served as Chairman twice. He was named EY Entrepreneur of the Year Award in 1997 and was awarded the Ellis Island Medal of Honor in 2018. In addition to NEHI, he serves on the Board of Trustees of McLean Hospital and several other non-profit organizations. Mr. von Rickenbach advises multiple companies, from startups to mature enterprises.

Mr. von Rickenbach holds a B.A. in Business Economics from Lucerne University in Switzerland, and an MBA from Harvard Business School.

Mr. von Rickenbach has lectured at the Harvard Business School, the MIT Sloan School of Management and the Tuck School of Business at Dartmouth.

Dr. Eve Slater is an Associate Clinical Professor of Medicine at Columbia University College of Physicians & Surgeons. Additionally, she serves on the Boards of the University of Medicine and Dentistry of New Jersey (nominated); Idera Pharmaceuticals, Cambridge, MA; iTheRx, San Diego, CA; the Council of the Rockefeller University, New York City, NY; and the Scientific Advisory Board of the Global Alliance for TB Drug Development, New York City, NY.

Prior to her role at Columbia, Dr. Slater served as Senior Vice President of Worldwide Policy at Pfizer, Inc. She has served as Assistant Secretary of Health for the U.S. Department of Health and Human Services. Prior to joining HHS, she spent over 19 years with Merck in a number of critical scientific, strategy and public policy positions. In 1983, she joined the Merck Research Laboratories in biochemical endocrinology and molecular biology, and in 1988, she was promoted to head the regulatory affairs department as VP and later SVP of Clinical and Regulatory Development. In 2001, she was named as SVP of External Policy for Merck Research Laboratories, and VP of Merck Corporate Public Affairs. An expert on HIV treatment research, she served as a member of both the U.S. Keystone National Policy Dialogue on HIV and the NIH Office of AIDS Research Advisory Council. An expert on the FDA, she was named to the Subcommittee of the FDA Science Board in 2007.

In 2001, Dr. Slater was appointed by President George W. Bush as Assistant Secretary of Health, the first woman to hold this position. In this role, she served HHS Secretary Tommy Thompson as chief health policy advisor, with special emphasis on e-health and innovation, biosecurity, clinical subjects’ protection, women’s health, eldercare and HIV/AIDS. After leaving HHS, she became a director and advisor to a number of biotechnology companies, including Vertex Pharmaceuticals, Cambridge, MA and Phase Forward, Waltham, MA.

Dr. Slater received her bachelor's degree from Vassar College (Phi Beta Kappa) and her medical degree from Columbia University (Alpha Omega Alpha). She received her training in internal medicine and cardiology at the Massachusetts General Hospital, where she was the first woman named as Chief Resident in Medicine and later led the Hypertension Unit. She also served as Assistant Professor of Medicine at Harvard Medical School. A Fellow of the American College of Cardiology, she continues to serve patients as an Associate Attending Physician at NY Presbyterian Hospital and Associate Professor of Medicine at Columbia.

Dr. Rick Weisblatt is the Senior Vice President for Provider Network and Health Services for Harvard Pilgrim Health Care, one of New England’s leading non-profit health plans. Founded in 1969, Harvard Pilgrim and its affiliates are licensed to provide comprehensive health insurance solutions in Massachusetts, Maine and New Hampshire. Its provider network has more than 22,000 physicians and 125 hospitals in Massachusetts, Maine, New Hampshire and Rhode Island. Harvard Pilgrim and its affiliates offer health and benefit plan solutions to over 1 million members in New England.

Dr. Weisblatt is responsible for all aspects of Harvard Pilgrim’s provider strategy. Under his leadership Harvard Pilgrim developed a nationally recognized program for hospital and physician pay-for-performance and recently implemented new risk arrangements intended to align the interests of physicians, health plans and patients. Dr. Weisblatt led the development of new network products including limited and tiered designs, health engagement incentive programs and member steerage programs.

Dr. Weisblatt has a doctorate in clinical psychology from the University of Maryland and his clinical interests have been in treating children, adolescents and couples.

Henri A. Termeer was appointed president of Genzyme Corporation in 1983, two years after the company's founding. He became its chief executive officer in 1985 and chairman in 1988. Under his leadership, Genzyme grew from a modest entrepreneurial venture to one of the world's leading biotechnology companies, and in 2007, Genzyme was chosen to receive the National Medal of Technology, the highest honor awarded by the President of the United States for technological innovation.
Mr. Termeer is recognized as a pioneer in developing and delivering treatments to patients with rare genetic diseases around the world. He was a trustee for the Boston Museum of Science, a member of the Massachusetts Institute of Technology Corporation and a member of the board of directors of Project HOPE, an international nonprofit health education and humanitarian assistance organization.

Widely acknowledged for his contributions to the biotechnology industry and health care field, Mr. Termeer served on the board of directors of both the Biotechnology Industry Organization and the Pharmaceutical Research and Manufacturers of America. He was a director of Massachusetts General Hospital and was a member of the board of fellows of Harvard Medical School. In addition, Mr. Termeer was deputy chairman of the Federal Reserve Bank of Boston's board of directors and a member of the board of directors of Abiomed Inc. He was also instrumental in founding the New England Healthcare Institute.

A Native of the Netherlands, Mr. Termeer studied economics at the Economische Hogeschool (Erasmus University, The Netherlands) and earned an M.B.A from the Darden School at the University of Virginia.